Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 30Thoracic 18Sarcoma 4Other solid neoplasm 4Lymphoid 4Head & Neck 4Tumor-Agnostic 3Genitourinary 3Breast 3Gynecologic 2Plasma cell 1Other hematologic neoplasm 1Dermatologic 1CNS 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

Cytarabine 102Cyclophosphamide 74fludarabine 45Idarubicin 39Decitabine 36Etoposide 35Azacitidine 34Methotrexate 31Daunorubicin 30Vincristine 28Dexamethasone 27venetoclax 25Busulfan 24Imatinib Mesylate 23Radiotherapy 20Mercaptopurine 20Granulocyte Colony-Stimulating Factor 20Dasatinib 19Peripheral Blood Stem Cell Transplantation 18Mitoxantrone 17Doxorubicin 17Immunotherapy, Adoptive 16Rituximab 15Asparaginase 15Tretinoin 14Cladribine 14fludarabine phosphate 13Prednisone 13Prednisolone 13Melphalan 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Immune Checkpoint Inhibitors × Other hematologic neoplasm × Clear all
NCT04353479 2020-04-20

Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia

Shanghai Jiao Tong University School of Medicine

Phase 2 Unknown
29 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡